Squarepoint
VOR icon

Squarepoint’s Vor Biopharma VOR Stock Holding History

Squarepoint’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$428K Sell
23,231
-2,251
-9% -$34.1K ﹤0.01% 3546
2026
Q1 		$455K Buy
25,482
+7,023
+38% +$99K ﹤0.01% 3390
2025
Q4 		$241K Buy
18,459
+13,730
+290% +$256K ﹤0.01% 3761
2025
Q3 		$230K Buy
+4,729
New +$190K ﹤0.01% 3853
2024
Q3 		– Sell
-2,614
Closed -$52.3K – 4748
2024
Q2 		$52.3K Buy
+2,614
New +$84.6K ﹤0.01% 3895
2023
Q4 		– Sell
-785
Closed -$33.3K – 4549
2023
Q3 		$33.3K Sell
785
-86
-10% -$4.66K ﹤0.01% 3670
2023
Q2 		$53.8K Buy
+871
New +$79.5K ﹤0.01% 3435

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Squarepoint's VOR Position: Q2 2026 in Review

Squarepoint reduced its Vor Biopharma (VOR) stake by 8.8% in Q2 2026, selling an estimated $34.1K and leaving 23,231 shares worth $428K. The position accounts for ﹤0.01% of the portfolio, ranked #3546.

Squarepoint first reported a position in VOR in Q2 2023 and has held it in 7 quarters since. The position peaked at $455K in Q1 2026. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Squarepoint held 23,231 shares of Vor Biopharma worth $428K as of Q2 2026.
  • Squarepoint sold 2,251 Vor Biopharma shares in Q2 2026, an estimated $34.1K.
  • Vor Biopharma made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3546 holding.
  • Squarepoint first reported a position in Vor Biopharma in Q2 2023 and has held it in 7 quarters since.
  • Squarepoint's Vor Biopharma position peaked at $455K in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.